MLR-1019

armesocarb

Lorem ipsum dolor sit amet. Et explicabo aliquam ut aliquid minus ut quasi necessitatibus ex corporis minima At omnis Quis eos commodi illum et velit nobis. Ut molestiae iste sed iste unde est dolores suscipit sit necessitatibus facilis et alias libero!

Download Presentation

Sample feature box 1

Eos illum quia sit inventore eligendi ut fuga error qui quae tempora. Sed quisquam saepe aut asperiores iure sed dolorem.

Sample feature box 2

Lorem ipsum dolor sit amet. Et explicabo aliquam ut aliquid minus ut quasi necessitatibus ex corporis minima.

Sample feature box 3

At omnis Quis eos commodi illum et velit nobis. Ut molestiae iste sed iste unde est dolores suscipit sit necessitatibus facilis et alias libero!

Targets

Parkinsons Disease

More than 10 million people worldwide have Parkinson’s disease (PD). It's an incurable, degenerative brain disorder affecting the nervous systems associated with motor symptoms and an array of non-motor complications. Initially, symptoms can be nearly unrecognizable and as simple a tiny tremor in the leg.

More Information

Timeline

Pre-Clinical
Phase 1
Phase 2
Phase 3
Pre-Clinical
Phase 1
Phase 2
Phase 3
Pre-Clinical
Phase 1
Phase 2
Phase 3
Pre-Clinical
Phase 1
Phase 2
Phase 3
Pre-Clinical
Phase 1
Phase 2
Phase 3

Manufacturing of MLR-1019 underway for Phase 2a trial

Sample additional feature box 2

Sample additional feature box 3

Sample additional feature box 4

For investors
‍Get our presentation.

Our full presentation contains in depth drug and market information. Get it now and have chat with our Investor Relations department to answer all your questions.

Download Presentation